Cargando…
Panel sequencing for clinically oriented variant screening and copy number detection in 142 untreated multiple myeloma patients
We employed a customized Multiple Myeloma (MM)-specific Mutation Panel (M(3)P) to screen a homogenous cohort of 142 untreated MM patients for relevant mutations in a selection of disease-specific genes. M(3)Pv2.0 includes 77 genes selected for being either actionable targets, potentially related to...
Autores principales: | Kortuem, K M, Braggio, E, Bruins, L, Barrio, S, Shi, C S, Zhu, Y X, Tibes, R, Viswanatha, D, Votruba, P, Ahmann, G, Fonseca, R, Jedlowski, P, Schlam, I, Kumar, S, Bergsagel, P L, Stewart, A K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771964/ https://www.ncbi.nlm.nih.gov/pubmed/26918361 http://dx.doi.org/10.1038/bcj.2016.1 |
Ejemplares similares
-
Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4
por: Zhu, Yuan Xiao, et al.
Publicado: (2019) -
MYC dysregulation in the progression of multiple myeloma
por: Misund, K, et al.
Publicado: (2019) -
Identification of PIKfyve kinase as a target in multiple myeloma
por: de Campos, Cecilia Bonolo, et al.
Publicado: (2020) -
Transcriptional profiles define drug refractory disease in myeloma
por: Zhu, Yuan Xiao, et al.
Publicado: (2022) -
“Direct to Drug” screening as a precision medicine tool in multiple myeloma
por: Bonolo de Campos, Cecilia, et al.
Publicado: (2020)